GU Cancers 2025 | Advancements and recent approvals in NMIBC: SunRISe-1, KEYNOTE-057, and more
The treatment landscape for non-muscle invasive bladder cancer (NMIBC) continues to evolve, with several recent FDA approvals such as pembrolizumab, nadofaragene firadenovec, and nogapendekin alfa inbakicept (NAI) with BCG. Roger Li, MD, H. Lee Moffitt Cancer Center, Tampa, FL, comments on recent findings from trials such as the SunRISe-1 (NCT04640623) and KEYNOTE-057 (NCT02625961), which explored novel approaches such as TAR-200, a drug-eluting device. These advancements highlight the potential for more effective and durable treatments in NMIBC. This interview took place at the ASCO GU Cancers Symposium 2025 in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
